RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regenxbio Inc (RGNX) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While there are some positive catalysts, the lack of strong proprietary trading signals, insider selling trends, and regulatory uncertainties make it prudent to hold off on purchasing the stock right now.
The MACD histogram is positive and expanding (0.242), indicating bullish momentum. RSI is at 72.487, which is neutral but approaching overbought territory. Moving averages are converging, showing no clear trend. The key support level is 7.114, with resistance at 8.203. The stock closed at $7.84, slightly above the pivot level, suggesting limited upside in the short term.
The FDA's reconsideration of UniQure's gene therapy candidate has positively impacted Regenxbio's RGX-121, leading to a 23% surge in its stock price recently. Additionally, the MACD indicates bullish momentum.
The stock's trend analysis suggests a 50% chance of a -1.59% decline in the next week.
No financial data available for analysis.
Analysts maintain a Buy or Overweight rating but have significantly reduced price targets (e.g., from $37 to $12 by Barclays, $30 to $26 by H.C. Wainwright) due to regulatory uncertainties and reduced peak penetration estimates for RGX-202.
